Comerica Bank increased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 0.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,144 shares of the medical equipment provider’s stock after acquiring an additional 293 shares during the quarter. Comerica Bank’s holdings in ABIOMED were worth $7,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Baillie Gifford & Co. raised its holdings in ABIOMED by 0.3% in the 3rd quarter. Baillie Gifford & Co. now owns 1,976,961 shares of the medical equipment provider’s stock valued at $333,316,000 after buying an additional 5,271 shares during the period. Janus Henderson Group PLC raised its holdings in ABIOMED by 102.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock valued at $181,553,000 after buying an additional 543,793 shares during the period. State Street Corp raised its holdings in ABIOMED by 2.3% in the 2nd quarter. State Street Corp now owns 1,071,191 shares of the medical equipment provider’s stock valued at $153,502,000 after buying an additional 23,933 shares during the period. Koch Industries Inc. raised its holdings in ABIOMED by 40,431.3% in the 2nd quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock valued at $794,000 after buying an additional 797,305 shares during the period. Finally, Scout Investments Inc. raised its holdings in ABIOMED by 3.3% in the 3rd quarter. Scout Investments Inc. now owns 551,949 shares of the medical equipment provider’s stock valued at $93,059,000 after buying an additional 17,706 shares during the period. 90.65% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at $229.50 on Friday. The stock has a market cap of $10,583.29, a PE ratio of 124.49, a price-to-earnings-growth ratio of 3.17 and a beta of 0.36. ABIOMED, Inc. has a one year low of $107.33 and a one year high of $255.42.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.20. The company had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.34 earnings per share. analysts expect that ABIOMED, Inc. will post 2.39 EPS for the current fiscal year.

Several analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective on the stock in a report on Tuesday, November 7th. BTIG Research restated a “hold” rating on shares of ABIOMED in a report on Sunday, February 4th. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Piper Jaffray Companies restated a “positive” rating and issued a $300.00 price objective (up from $220.00) on shares of ABIOMED in a report on Thursday, February 1st. Finally, Leerink Swann boosted their price objective on shares of ABIOMED from $200.00 to $265.00 and gave the company an “outperform” rating in a report on Friday, January 19th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $263.86.

COPYRIGHT VIOLATION WARNING: “Comerica Bank Purchases 293 Shares of ABIOMED, Inc. (ABMD)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/comerica-bank-purchases-293-shares-of-abiomed-inc-abmd/1854257.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.